SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4636-4642. Prepublished online as a Blood First Edition Paper on February 14, 2006; DOI 10.1182/blood-2005-11-4429. This Article Full Text (PDF) All Versions of this Article: 2005-11-4429v1 107/12/4636    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ferme, C. Articles by Gisselbrecht, C. Search for Related Content PubMed PubMed Citation Articles by Ferme, C. Articles by Gisselbrecht, C. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 10, 2005 Accepted February 3, 2006 Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Christophe Ferme*, Nicolas Mounier, Olivier Casasnovas, Pauline Brice, Marine Divine, Anne Sonet, Fahdela Bouafia, Aspasia Bastard-Stamatoullas, Dominique Bordessoule, Laurent Voillat, Oumedaly Reman, Michel Blanc, and Christian Gisselbrecht Department of Medicine, Institut Gustave Roussy, Villejuif, France Hematology, Hopital Saint-Louis, Paris, France Hematology, CHU de Dijon, Dijon, France Hematology, CHU Henri Mondor, Creteil, France Hematology, Universite Catholique de Louvain, Yvoir, Belgium Hematology, Hospices Civils de Lyon, Pierre-Benite, France Hematology, Centre Becquerel, Rouen, France Hematology, CHU de Limoges, Limoges, France Hematology, CHU de Besancon, Besancon, France Hematology, CHU de Caen, Caen, France Hematology, Hospitalier de Chambery, Chambery, France * Corresponding author; email: ferme{at}igr.fr. From 1989 to 1996, 533 eligible patients with stage IIIB/IV Hodgkin lymphoma (HL) were randomly assigned to receive 6 cycles of hybrid MOPP/ABV (n = 266) or ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone) (n = 267). Patients in complete remission (CR) or partial response of at least 75% after 6 cycles received 2 cycles of consolidation chemotherapy (CT) (n = 208) or sub-total nodal irradiation (RT) (n = 210). A better survival probability was observed after ABVPP alone: the 10-year overall survival (OS) estimates were 90% for ABVPPx8, 78% for MOPP/ABVx8, 82% for MOPP/ABV+RT, and 77% for ABVPPx6+RT (P = .03); and the 10-year disease-free survival (DFS) estimates were 70%, 76%, 79% and 76% respectively (p =.09). The 10-year DFS estimates for patients treated with consolidation CT or RT were 73% and 78% (P = .07), and OS estimates were 84% and 79%, respectively (P = .29). These results showed that RT was not superior to consolidation CT after a doxorubicin-induced CR in patients with advanced HL. An analysis of competing risks identified age above 45 years as a significant risk factor for death, relapse and second cancers. Prospective evaluation of late adverse events may improve the management of patients with HL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020